Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835293 | 0.80 | ALOX5 (0.42) | ALOX5PTGS1PTGS2BCHEHTR6 | |
| SCHEMBL13877233 | 0.80 | ALOX5 (0.65) | ALOX5PTGS1PTGS2BCHEHTR6 | |
| SCHEMBL13877230 | 0.76 | BCHE (0.55) | PTGS1PTGS2BCHEHTR6PTGDR2 | |
| SCHEMBL13877229 | 0.75 | PTGDR2 (0.50) | BCHEPTGDR2 | |
| Ammonia Solution, Strong SCHEMBL906134 | 0.73 | HTR6 (0.51) | BCHEHTR6PTGDR2HRH1TBXA2R | |
| SCHEMBL12325728 | 0.71 | BCHE (0.45) | PTGS1PTGS2BCHEHTR6PTGDR2 | |
| SCHEMBL906133 | 0.71 | PTGDR2 (0.41) | ALOX5PTGS1PTGS2BCHEHTR6 | |
| SCHEMBL10128525 | 0.69 | PTGDR2 (0.43) | BCHEHTR6PTGDR2 | |
| SCHEMBL7467529 | 0.69 | HTR6 (0.47) | BCHEHTR6PTGDR2HRH1TBXA2R | |
| SCHEMBL906131 | 0.68 | BCHE (0.53) | BCHEHTR6PTGDR2HSD17B10HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | ALOX5 69/4885PTGS1 10/4885PTGS2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.